One of the secondary issues which cropped up with Nina Davuluri winning Miss America is that it seems implausible that someone with her complexion would be able to win any Indian beauty contest. A quick skim of Google images “Miss India” will make clear the reality that I’m alluding to. The Indian beauty ideal, especially for females, is skewed to the lighter end of the complexion distribution of native South Asians. Nina Davuluri herself is not particularly dark skinned if you compared her to the average South Asian; in fact she is likely at the median. But it would be surprising to see a woman who looks like her held up as conventionally beautiful in the mainstream Indian media. When I’ve pointed this peculiar aspect out to Indians* some of them of will submit that there are dark skinned female celebrities, but when I look up the actresses in question they are invariably not very dark skinned, though perhaps by comparison to what is the norm in that industry they may be. But whatever the cultural reality is, the fraught relationship of color variation to aesthetic variation prompts us to ask, why are South Asians so diverse in their complexions in the first place? A new paper in PLoS Genetics , The Light Skin Allele of SLC24A5 in South Asians and Europeans Shares Identity by Descent , explores this genetic question in depth.
1) BMY will look at EXEL more closely for combinations due to their 1L failure in lung cancer using Opdivo. RCC, and Lung are two top markets for IO drugs and Exelixis presumably works in both. There was a mention of potential in lung cancer combination trial during the earnings call.
2) Japan deal could be made now that earnings are out, they might be asking for more money due to Cabosun now being pursued for FDA approval for 1L RCC albeit confidentially.
3) After Japanese deal, and Ipsen European payment Exelixis might have a larger sum of money to pay down the convertible debt in cash and stock combination.
4) Potential bidding war for Exelixis between BMY, Pfizer, and Roche.
What researchers have found is that individual hair follicles have different expression of genes within the follicle. Each gene expression reacts differently to androgen. Some genes inhibit follicle health and some increase follicle health. Since each follicle is independent of one another, each gene expression is also independent of one another. This is why hair transplants work. The follicles on your head might be dying, but the ones in other areas of your body are not, so doctors can simply move them. The transplanted hair follicle will not die because the genes associated with that follicle are not negatively affected by androgen, no matter what area of the body they’re in. Nothing like back hair on your head! The process that allows a specific gene to be expressed in a certain follicle isn’t yet understood. What is known is that the programming occurs in the pattern processing during development.